Total Revenue (USD, thousands)

Cost of Goods Sold (COGS) (USD, thousands)

Selling, General, and Administrative Expenses (USD, thousands)

Research and Development (R&D) (USD, thousands)

Depreciation and Amortization (D&A) (USD, thousands)

Interest Expense (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

Earnings Per Share (EPS) - Basic (USD)

Earnings Per Share (EPS) - Diluted (USD)

fbf2bee4c197f61ec67bbf82764cb5fd1ab44dbb5374a0e4ea99e14ad8f411dc

United States

International

Total Revenue

bfb3379ab64c9e810f6bfe0f165189213578c2a0c543ae95b228be81d4aa608e

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

b8a242dcdfd37210498087d908f8deafe4c7183438359ed62c54f420772e4afa

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Goodwill (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

36769030057dea8b4243afde793c08887a23a074dfce526244be2ca737c18bd7

Inari Medical, Inc. (NARI) is a medical device company specializing in innovative, minimally invasive solutions for venous and vascular diseases. The company develops and commercializes catheter-based mechanical thrombectomy devices and accessories designed to treat conditions such as venous thromboembolism (VTE), chronic venous disease, and critical limb-threatening ischemia (CLTI). NARI's mission is to improve patient outcomes by establishing its treatments as the standard of care in these underserved medical areas.  **[0001531048-24-000024_nari-20231231.htm:5]** **[0001531048-24-000060_nari-20240930.htm:28]** **[0001531048-24-000024_nari-20231231.htm:41]** 

1. **Venous Thromboembolism (VTE)** - Provides solutions for treating deep vein thrombosis (DVT) and pulmonary embolism (PE) using catheter-based mechanical thrombectomy devices like the FlowTriever and ClotTriever systems.  **[0001531048-24-000024_nari-20231231.htm:5]** **[0001531048-24-000060_nari-20240930.htm:28]** **[0001531048-24-000024_nari-20231231.htm:41]** 
2. **Emerging Therapies** - Addresses chronic venous disease, critical limb-threatening ischemia (CLTI), acute limb ischemia (ALI), dialysis access management, and arterial thromboembolism with innovative devices such as the LimFlow System and VenaCore.  **[0001531048-24-000024_nari-20231231.htm:5]** **[0001531048-24-000060_nari-20240930.htm:28]** **[0001531048-24-000024_nari-20231231.htm:41]**

274cd5842bae9cfc2a0593b002fcf7468bb607e2df34204d12c315c2cd90e9e7

1. Given the GAAP operating loss of $13.6 million in Q3 2024 compared to a GAAP operating income of $2.1 million in the prior year, can you detail the specific initiatives that will drive you to sustained GAAP operating profitability in the first half of 2025, and what obstacles might impede this goal?
2. With R&D expenses increasing significantly due to a one-time non-cash impairment charge and other factors, how do you plan to reduce R&D expenses as a percentage of revenue without hindering innovation and product development that are crucial for maintaining your competitive edge?
3. Considering the current consensus projects 18% growth for 2025, but you aspire to be a 20% grower, what concrete strategies are in place to bridge this gap, and what risks could prevent you from achieving the higher growth rate?
4. As you anticipate positive results from the PEERLESS trial, is there a concern that this could create a class effect benefiting other companies in the mechanical thrombectomy space, and how will you ensure that Inari captures the majority of the potential market expansion?
5. Despite international revenue growing by 76.4%, it remains a small fraction of total revenue; what are the primary challenges in scaling international sales to reach your goal of it accounting for at least 20% of Inari's revenue, and what strategies are you implementing to overcome these hurdles?

99262c80aeda4127dab09910fabb9fb439f7d4d3a7a70c867945d16a3afef46b

23794d91c53ae875c8e247d72561e35d9d06ee07c70c9e0dbcc977a6d161504a

Inari Medical Inc (NARI)

Financials